Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

Margaret Von Mehren, Cathryn Rankin, John R. Goldblum, George D. Demetri, Vivien Bramwell, Christopher Ryan, Ernest Borden

    Research output: Contribution to journalArticle

    75 Citations (Scopus)

    Abstract

    BACKGROUND: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS: Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.

    Original languageEnglish (US)
    Pages (from-to)770-776
    Number of pages7
    JournalCancer
    Volume118
    Issue number3
    DOIs
    StatePublished - Feb 1 2012

    Fingerprint

    Sarcoma
    Liposarcoma
    Leiomyosarcoma
    Blood Vessels
    Disease-Free Survival
    fms-Like Tyrosine Kinase 3
    Proto-Oncogene Proteins c-sis
    Vascular Endothelial Growth Factor Receptor-1
    Protein-Tyrosine Kinases
    Appointments and Schedules
    sorafenib
    Survival
    Therapeutics

    Keywords

    • angiosarcoma
    • leiomyosarcoma
    • liposarcoma
    • solitary fibrous tumor
    • tyrosine kinase inhibitor

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Von Mehren, M., Rankin, C., Goldblum, J. R., Demetri, G. D., Bramwell, V., Ryan, C., & Borden, E. (2012). Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer, 118(3), 770-776. https://doi.org/10.1002/cncr.26334

    Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. / Von Mehren, Margaret; Rankin, Cathryn; Goldblum, John R.; Demetri, George D.; Bramwell, Vivien; Ryan, Christopher; Borden, Ernest.

    In: Cancer, Vol. 118, No. 3, 01.02.2012, p. 770-776.

    Research output: Contribution to journalArticle

    Von Mehren, M, Rankin, C, Goldblum, JR, Demetri, GD, Bramwell, V, Ryan, C & Borden, E 2012, 'Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas', Cancer, vol. 118, no. 3, pp. 770-776. https://doi.org/10.1002/cncr.26334
    Von Mehren, Margaret ; Rankin, Cathryn ; Goldblum, John R. ; Demetri, George D. ; Bramwell, Vivien ; Ryan, Christopher ; Borden, Ernest. / Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. In: Cancer. 2012 ; Vol. 118, No. 3. pp. 770-776.
    @article{721f2258d1444f3ca2f48d9266758b77,
    title = "Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas",
    abstract = "BACKGROUND: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS: Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.",
    keywords = "angiosarcoma, leiomyosarcoma, liposarcoma, solitary fibrous tumor, tyrosine kinase inhibitor",
    author = "{Von Mehren}, Margaret and Cathryn Rankin and Goldblum, {John R.} and Demetri, {George D.} and Vivien Bramwell and Christopher Ryan and Ernest Borden",
    year = "2012",
    month = "2",
    day = "1",
    doi = "10.1002/cncr.26334",
    language = "English (US)",
    volume = "118",
    pages = "770--776",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

    AU - Von Mehren, Margaret

    AU - Rankin, Cathryn

    AU - Goldblum, John R.

    AU - Demetri, George D.

    AU - Bramwell, Vivien

    AU - Ryan, Christopher

    AU - Borden, Ernest

    PY - 2012/2/1

    Y1 - 2012/2/1

    N2 - BACKGROUND: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS: Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.

    AB - BACKGROUND: Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS. METHODS: The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease. RESULTS: Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas. CONCLUSIONS: Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.

    KW - angiosarcoma

    KW - leiomyosarcoma

    KW - liposarcoma

    KW - solitary fibrous tumor

    KW - tyrosine kinase inhibitor

    UR - http://www.scopus.com/inward/record.url?scp=84856233838&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84856233838&partnerID=8YFLogxK

    U2 - 10.1002/cncr.26334

    DO - 10.1002/cncr.26334

    M3 - Article

    C2 - 21751200

    AN - SCOPUS:84856233838

    VL - 118

    SP - 770

    EP - 776

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 3

    ER -